Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial
- PMID: 12719883
- DOI: 10.1007/s00280-003-0620-1
Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial
Abstract
Objective: To determine which hydration (saline, saline + mannitol, or saline + furosemide) is associated with least cisplatin nephrotoxicity.
Methods: We randomized 49 women who received cisplatin (75 mg/m(2) every 3 weeks) into one of the three hydration arms. The 24-h creatinine clearance was measured before and on day 6 after cisplatin infusion. The patients of each arm received 2 l of saline hydration. In the saline + furosemide arm, 40 mg of furosemide was given after hydration. In the saline + mannitol arm, 50 g of mannitol was mixed with the cisplatin.
Results: For the first cycle of chemotherapy, 15 women were randomized to saline, 17 to saline + furosemide, and 17 to saline + mannitol. For each group, the creatinine clearances before cisplatin infusion were (means+/-SD, milliliters per minute) 84.5+/-26.8, 82.5+/-24.0 and 87.4+/-25.6, and after cisplatin infusion were 79.1+/-31.9, 68.7+/-21.5, and 56.4+/-22.9, respectively. The decreases in creatinine clearance were similar between the saline group and the saline + furosemide group ( P=0.66), but different between the saline + mannitol group and the saline group ( P=0.02) or the saline + furosemide group ( P=0.02). As each woman received multiple courses of cisplatin, 15 who received saline contributed 41 paired datasets, 17 who received saline + furosemide contributed 49 paired datasets, and 17 who received saline + mannitol contributed 36 paired datasets showed similar patterns.
Conclusions: Hydration with saline or saline + furosemide appears to be associated with less cisplatin nephrotoxicity than saline + mannitol.
Similar articles
-
Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.Indian J Cancer. 1996 Dec;33(4):168-70. Indian J Cancer. 1996. PMID: 9254992 Clinical Trial.
-
High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.Cancer Treat Rep. 1981 Jan-Feb;65(1-2):73-8. Cancer Treat Rep. 1981. PMID: 6784924 Clinical Trial.
-
A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.J Oncol Pharm Pract. 2010 Sep;16(3):167-71. doi: 10.1177/1078155209346071. Epub 2009 Sep 16. J Oncol Pharm Pract. 2010. PMID: 19759050
-
Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.Gynecol Oncol. 1993 Aug;50(2):147-58. doi: 10.1006/gyno.1993.1184. Gynecol Oncol. 1993. PMID: 8375728 Review.
-
The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.Ann Pharmacother. 2012 Feb;46(2):276-81. doi: 10.1345/aph.1Q333. Epub 2012 Jan 31. Ann Pharmacother. 2012. PMID: 22298599 Review.
Cited by
-
Efficacy of Short Hydration for Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatients: SHORTCIS Trial.Asian Pac J Cancer Prev. 2022 Oct 1;23(10):3323-3330. doi: 10.31557/APJCP.2022.23.10.3323. Asian Pac J Cancer Prev. 2022. PMID: 36308355 Free PMC article. Clinical Trial.
-
Effect of prehydration solution on hearing threshold after chemotherapy in patients with head and neck cancers: a retrospective study.J Yeungnam Med Sci. 2023 Apr;40(2):164-171. doi: 10.12701/jyms.2022.00276. Epub 2022 Aug 24. J Yeungnam Med Sci. 2023. PMID: 35999669 Free PMC article.
-
A systematic review for prevention of cisplatin-induced nephrotoxicity using different hydration protocols and meta-analysis for magnesium hydrate supplementation.Clin Exp Nephrol. 2024 Jan;28(1):1-12. doi: 10.1007/s10157-023-02386-2. Epub 2023 Aug 2. Clin Exp Nephrol. 2024. PMID: 37530867 Review.
-
Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas.Cancers (Basel). 2016 Feb 16;8(2):21. doi: 10.3390/cancers8020021. Cancers (Basel). 2016. PMID: 26891330 Free PMC article.
-
The identification of dual protective agents against cisplatin-induced oto- and nephrotoxicity using the zebrafish model.Elife. 2020 Jul 28;9:e56235. doi: 10.7554/eLife.56235. Elife. 2020. PMID: 32720645 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials